Related Experiment Videos
[Vascular changes in the pathogenesis of systemic sclerosis]
J H W Distler1, J R Kalden, S Gray
1Department of Internal Medicine III, University of Erlangen-Nuremberg, Germany. Oliver.Distler@usz.ch
Zeitschrift Fur Rheumatologie
|December 18, 2004
Summary
Systemic sclerosis (SSc) involves impaired blood vessel formation. While vascular endothelial growth factor (VEGF) is elevated in SSc patients, its role in the disease
Area of Science:
- Connective tissue diseases
- Vascular biology
- Immunology
Context:
- Systemic sclerosis (SSc), a connective tissue disease, presents with vascular abnormalities.
- Early SSc stages show inflammation and endothelial cell apoptosis, leading to impaired angiogenesis.
- Later stages involve excessive extracellular matrix deposition in skin and organs.
Purpose:
- To investigate the role of vascular endothelial growth factor (VEGF) in systemic sclerosis (SSc).
- To understand the paradox of overexpressed VEGF despite insufficient angiogenesis in SSc.
- To explore VEGF's potential protective effects versus detrimental long-term consequences.
Summary:
- Systemic sclerosis (SSc) patients exhibit elevated serum markers of endothelial cell damage.
- Vascular endothelial growth factor (VEGF) is paradoxically overexpressed in SSc skin, yet angiogenesis is impaired.
- Elevated VEGF levels in diffuse SSc and non-ulcerated patients suggest a potential protective role against ischemia, but long-term uncontrolled overexpression may cause detrimental vascular changes.
Impact:
- Findings suggest VEGF's complex role in SSc pathogenesis, potentially influencing ischemic conditions.
- Understanding VEGF dysregulation may offer insights into therapeutic strategies targeting vascular complications in SSc.
- Further research into VEGF's dual effects is crucial for managing SSc-related vascular issues.